A new study published in the December 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, shows that other approaches to overcome acquired resistance should be considered.
Researchers looked at NSCLC patients with histologically confirmed ALK rearrangements or EGFR mutations who were treated with crizotinib or erlotinib at the University of Colorado Cancer Center between May 2005 and December 2011.
Of the 51 patients whose cancer grew eventually on the targeted drugs, 25 were deemed suitable for local ablative therapy radiotherapy or surgery) to the site of progression, and then continued on the same drug. The use of this strategy prolonged the duration of disease control by the drug by 6.2 months, on top of the median of 9.8 months initial disease control. The benefit was most marked in patients who only experienced isolated growth in the brain - this group had another median 7.1 months of disease control before further growth either in the body and brain.
While the authors point out study limitations and the need for further research, they say their experience suggests that when NSCLC patients with EGFR mutations or ALK rearrangements "progress on erlotinib or crizotinib, respectively, and the progression occurs in only a limited number of sites (oligoprogressive disease) it may be reasonable to consider LAT to the sites of progression and continuation of the TKI."
The lead author of this work is IASLC member Dr. Andrew Weickhardt. Co-authors include IASLC members Dr. Paul Bunn, Dr. Dara Aisner, Dr. Laurie Gaspar, Dr. Robert Doebele and Dr. Ross Camidge.
International Association for the Study of Lung Cancer
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
International Association for the Study of Lung Ca. "Different Approach Suggested After Progression In NSCLC Patients." Medical News Today. MediLexicon, Intl., 19 Nov. 2012. Web.
24 Oct. 2016. <http://www.medicalnewstoday.com/releases/252910.php>
International Association for the Study of Lung Ca. (2012, November 19). "Different Approach Suggested After Progression In NSCLC Patients." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.